Title: A single-arm, open-label, phase II trial of entrectinib in patients with advanced tumours harbouring NTRK fusions or ROS1 gene rearrangements detected by comprehensive genomic profiling.

Trial Summary:

The aim of this ASPiRATION and MoST substudy to assess the clinical activity of entrectinib in adult patients with advanced cancers harbouring NTRK or ROS1 gene alterations.

Supported By:

 

Eligibility:

Adult patients with advanced cancers harbouring NTRK fusions or ROS1 gene rearrangements. NSCLC patients with ROS1 gene alterations must be FISH-negative, i.e. not eligible for reimbursed ROS1-targeted treatment.

Registration ID:

ACTRN12621000284864

Participation:

National

Status:

Closed

Activation Date:

21/05/2021

Chairs:

Dr Peey-Sei Kok, A/Prof Tom John, and Dr Subotheni Thavaneswaran

Contact:

most.study@sydney.edu.au